227 related articles for article (PubMed ID: 34725436)
41. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract][Full Text] [Related]
42. Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors.
Shinohara H; Sawado R; Nakagawa M; Hattori A; Yamagata K; Tauchi K; Ito J; Kuwahara Y; Okuda T; Ogawa C; Kitabayashi I
Mol Ther Oncolytics; 2022 Dec; 27():14-25. PubMed ID: 36212776
[TBL] [Abstract][Full Text] [Related]
43. Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling.
Khan H; Ni Z; Feng H; Xing Y; Wu X; Huang D; Chen L; Niu Y; Shi G
Phytomedicine; 2021 Oct; 91():153706. PubMed ID: 34517264
[TBL] [Abstract][Full Text] [Related]
44. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
Knutson SK; Kawano S; Minoshima Y; Warholic NM; Huang KC; Xiao Y; Kadowaki T; Uesugi M; Kuznetsov G; Kumar N; Wigle TJ; Klaus CR; Allain CJ; Raimondi A; Waters NJ; Smith JJ; Porter-Scott M; Chesworth R; Moyer MP; Copeland RA; Richon VM; Uenaka T; Pollock RM; Kuntz KW; Yokoi A; Keilhack H
Mol Cancer Ther; 2014 Apr; 13(4):842-54. PubMed ID: 24563539
[TBL] [Abstract][Full Text] [Related]
45. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.
Zhang L; Li HT; Shereda R; Lu Q; Weisenberger DJ; O'Connell C; Machida K; An W; Lenz HJ; El-Khoueiry A; Jones PA; Liu M; Liang G
Cancer Lett; 2022 Nov; 548():215899. PubMed ID: 36087682
[TBL] [Abstract][Full Text] [Related]
46. Unlocking adult T-cell leukemia/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1/2 inhibition.
Tavakoli Shirazi P; Bywater MJ
Immunol Cell Biol; 2024; 102(5):298-301. PubMed ID: 38606590
[TBL] [Abstract][Full Text] [Related]
47. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
Liu TP; Lo HL; Wei LS; Hsiao HH; Yang PM
Anticancer Drugs; 2015 Feb; 26(2):139-47. PubMed ID: 25203626
[TBL] [Abstract][Full Text] [Related]
48. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
Xia H; Ooi LL; Hui KM
PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
[TBL] [Abstract][Full Text] [Related]
49. EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair.
Ezhkova E; Lien WH; Stokes N; Pasolli HA; Silva JM; Fuchs E
Genes Dev; 2011 Mar; 25(5):485-98. PubMed ID: 21317239
[TBL] [Abstract][Full Text] [Related]
50. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
51. Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib.
Salani F; Latarani M; Casadei-Gardini A; Gangadharannambiar P; Fornaro L; Vivaldi C; Pecora I; Massa V; Marisi G; Canale M; Ulivi P; Scartozzi M; Eccleston M; Masi G; Crea F
Epigenomics; 2022 May; 14(9):507-517. PubMed ID: 35473355
[TBL] [Abstract][Full Text] [Related]
52. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
53. Recent advances in EZH2-based dual inhibitors in the treatment of cancers.
Yang X; Xu L; Yang L
Eur J Med Chem; 2023 Aug; 256():115461. PubMed ID: 37156182
[TBL] [Abstract][Full Text] [Related]
54. Inhibitors of the Histone Methyltransferases EZH2/1 Induce a Potent Antiviral State and Suppress Infection by Diverse Viral Pathogens.
Arbuckle JH; Gardina PJ; Gordon DN; Hickman HD; Yewdell JW; Pierson TC; Myers TG; Kristie TM
mBio; 2017 Aug; 8(4):. PubMed ID: 28811345
[TBL] [Abstract][Full Text] [Related]
55. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
Dou F; Tian Z; Yang X; Li J; Wang R; Gao J
Drug Discov Ther; 2022 Dec; 16(6):297-299. PubMed ID: 36310058
[TBL] [Abstract][Full Text] [Related]
56. EZH1 in germ cells safeguards the function of PRC2 during spermatogenesis.
Mu W; Starmer J; Shibata Y; Yee D; Magnuson T
Dev Biol; 2017 Apr; 424(2):198-207. PubMed ID: 28254491
[TBL] [Abstract][Full Text] [Related]
57. [Novel epigenetic therapies for multiple myeloma].
Mimura N
Rinsho Ketsueki; 2021; 62(4):314-320. PubMed ID: 33967157
[TBL] [Abstract][Full Text] [Related]
58. Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma.
Wang Z; Dai J; Yan J; Zhang Y; Yin Z
J Cell Mol Med; 2019 Jul; 23(7):4770-4778. PubMed ID: 31087496
[TBL] [Abstract][Full Text] [Related]
59. The polycomb proteins EZH1 and EZH2 co-regulate chromatin accessibility and nephron progenitor cell lifespan in mice.
Liu H; Hilliard S; Kelly E; Chen CH; Saifudeen Z; El-Dahr SS
J Biol Chem; 2020 Aug; 295(33):11542-11558. PubMed ID: 32554463
[TBL] [Abstract][Full Text] [Related]
60. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
